ReviewAnnual review of public health2018
Treatment and Prevention of Opioid Use Disorder: Challenges and Opportunities.
Review in Annual review of public health, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 84 citations in OpenAlex.
- The difference-making role of staff support in implementing nurse care management for opioid use disorder treatment: A configurational analysis.Journal of substance use and addiction treatment · 2025Trial
- The payer's role in addressing the opioid epidemic: It's more than money.Journal of substance abuse treatment · 2019Trial
- Impact of Depressive Symptom Severity on Buprenorphine/Naloxone and Methadone Outcomes in People With Prescription-Type Opioid Use Disorder: Results From a Pragmatic Randomized Controlled Trial.Journal of dual diagnosisTrial
- Reframing Buprenorphine as a Pharmacologic Modifier of Opioid-Induced Respiratory Depression in the Fentanyl Era.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Creating a Classification System of Opioid Use Disorder Treatment Policies: A Research Protocol.Substance use & addiction journal · 2025Article
- Development, Validity, and Acceptability of the Peer Recovery Coach (PRC) Service Checklist for Medication for Opioid Use Disorder (MOUD) Support.Substance use & misuse · 2025Article
- Utilization of long-acting injectable monthly depot buprenorphine for opioid use disorder (OUD) in Kentucky, before and after COVID-19 related buprenorphine access policy changes.Journal of substance use and addiction treatment · 2024Article
- Centering culture in the treatment of opioid use disorder with American Indian and Alaska Native Communities: Contributions from a National Collaborative Board.American journal of community psychology · 2023Article
- Risk factors for opioid use disorder after severe burns in adults.American journal of surgery · 2023Article
- Association between treatment setting and outcomes among oregon medicaid patients with opioid use disorder: a retrospective cohort study.Addiction science & clinical practice · 2022Article
- Individual, interpersonal, and neighborhood measures associated with opioid use stigma: Evidence from a nationally representative survey.Social science & medicine (1982) · 2022Article
- Variations in national availability of waivered buprenorphine prescribers by racial and ethnic composition of zip codes.Substance abuse treatment, prevention, and policy · 2022Article
- Assessment of Community-Level Vulnerability and Access to Medications for Opioid Use Disorder.JAMA network open · 2022Article
- Alternative use of buprenorphine among people who use opioids in three U.S. Cities.Substance abuse · 2022Article
- A review of sleep disturbance in adults prescribed medications for opioid use disorder: potential treatment targets for a highly prevalent, chronic problem.Sleep medicine · 2021Review
- Adapting behavioural interventions to compensate for cognitive dysfunction in persons with opioid use disorder.General psychiatry · 2021Review
- Intervention in an opioid overdose event increases interest in treatment among individuals with opioid use disorder.Substance abuse · 2021Article
- Research priorities for expanding access to methadone treatment for opioid use disorder in the United States: A National Institute on Drug Abuse Center for Clinical Trials Network Task Force report.Substance abuse · 2021Article
- Opioid agonist and antagonist use and the gut microbiota: associations among people in addiction treatment.Scientific reports · 2020Article
- Situating the Continuum of Overdose Risk in the Social Determinants of Health: A New Conceptual Framework.The Milbank quarterly · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Treatment for opioid use disorder in the United States evolved in response to changing federal policy and advances in science. Inpatient care began in 1935 with the US Public Health Service Hospitals in Lexington, Kentucky, and Fort Worth, Texas. Outpatient clinics emerged in the 1960s to provide aftercare. Research advances led to opioid agonist and opioid antagonist therapies. When patients complete opioid withdrawal, return to use is often rapid and frequently deadly. US and international authorities recommend opioid agonist therapy (i.e., methadone or buprenorphine). Opioid antagonist therapy (i.e., extended-release naltrexone) may also inhibit return to use. Prevention efforts emphasize public and prescriber education, use of prescription drug monitoring programs, and safe medication disposal options. Overdose education and naloxone distribution promote access to rescue medication and reduce opioid overdose fatalities. Opioid use disorder prevention and treatment must embrace evidence-based care and integrate with physical and mental health care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.